Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease
This meta-analysis included eight randomized controlled trials evaluating the effects of cannabinoids in patients with Crohn's disease and ulcerative colitis. The findings demonstrated a significant improvement in clinical disease activity among patients with Crohn's disease and improved quality of life across both Crohn's disease and ulcerative colitis. However, cannabinoids did not significantly improve objective markers of inflammation, including endoscopic findings and inflammatory biomarkers. The authors conclude that cannabinoids may alleviate symptoms and enhance quality of life in patients with inflammatory bowel disease, but current evidence does not support a direct anti-inflammatory effect.
Background and Objective
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder that significantly affects patients' quality of life. With the increasing use of medical cannabis worldwide, interest has grown in the potential therapeutic role of cannabinoids for IBD. This updated meta-analysis aimed to evaluate the efficacy of cannabinoid-based therapies by synthesizing evidence from randomized controlled trials (RCTs) involving patients with CD and UC.
Methods
A systematic search of PubMed, Embase, CENTRAL, and CINAHL identified randomized controlled trials comparing cannabinoid-based therapies with control treatments in patients with confirmed IBD. Eight RCTs met the inclusion criteria, including four studies of Crohn's disease, three studies of ulcerative colitis, and one study involving both conditions. Random-effects meta-analysis was performed to evaluate clinical disease activity, health-related quality of life, endoscopic outcomes, and objective inflammatory biomarkers.
Key Findings
The pooled analysis demonstrated a significant improvement in clinical disease activity among patients with Crohn's disease receiving cannabinoid-based therapy. In contrast, no statistically significant improvement in clinical disease activity was observed in patients with ulcerative colitis.
Cannabinoid treatment was also associated with improved patient-reported quality of life across the overall IBD population, with similar improvements observed in both Crohn's disease and ulcerative colitis.
However, no statistically significant differences were identified between cannabinoid-treated and control groups regarding endoscopic disease activity or objective inflammatory biomarkers, suggesting that the observed symptomatic improvements were not accompanied by measurable changes in intestinal inflammation.
Conclusion
This meta-analysis suggests that cannabinoid-based therapies may improve clinical symptoms in Crohn's disease and enhance patient-reported quality of life in individuals with inflammatory bowel disease. However, current evidence does not demonstrate significant improvements in objective measures of intestinal inflammation or endoscopic healing. While cannabinoids may have a role as adjunctive therapy for symptom management, additional large, high-quality randomized controlled trials are needed to better define their therapeutic efficacy and their impact on long-term disease outcomes.
Source: Kang H, Schmoyer CJ, Weiss A, Lewis JD. Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 Feb 6;31(2):450-460. doi: 10.1093/ibd/izae158. PMID: 39197096.
